Skip to main content

Table 4 Patient background and molecular status of analysis for GBM cohort

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

Cohort Alla Cohort 1 Cohort 2 P-valueb
Total 453 260 193  
Mean Age at diagnosis 61.0 59.3 63.3 0.0007
Sex M/F 249/204 152/108 97/96 0.0827
Locationc
 Cereberal with frontal involvement 152 (34) 87 (33) 65 (34) 0.985
 Cerebral (other) 277 (61) 160 (62) 117 (61)
 Other 22 (5) 13 (5) 9 (5)
KPS
 100 56 (12) 12 (5) 44 (23) <0.0001
 90 132 (29) 81 (31) 51 (26)
 80 111 (25) 73 (28) 38 (20)
 70 85 (19) 53 (20) 32 (17)
  − 60 69 (15) 41 (16) 28 (15)
TERT/MGMT
 Mut/Met 88 (19) 48 (18) 40 (21) 0.921
 Mut/Un-met 175 (39) 100 (38) 75 (39)
 Wt/Met 64 (14) 38 (15) 26 (13)
 Wt/Un-met 126 (28) 74 (28) 52 (27)
Surgery
 Removal 421 (93) 238 (92) 183 (95)  
 Biopsy only 32 (7) 22 (8) 10 (5) 0.178
  1. aIDH1/2 mutated cases were excluded for this analysis (see Materials and methods in the manuscript)
  2. bStudent’s t-test was applied for the statistical analysis of age, and Pearson’s chi-square test was done for others
  3. cData of Location was not available in 2 cases of Cohort2
  4. F Female, GBM glioblastoma, KPS Karnofsky Performance Status, M Male, Met MGMT methylated, Mut TERT mutated, N/A not available, Un-met MGMT unmethylated, wt TERT wild-type